In:
Journal of Comparative Effectiveness Research, Becaris Publishing Limited, Vol. 12, No. 5 ( 2023-05)
Abstract:
Whether PD-1 immune checkpoint inhibitor plus chemotherapy is superior to bevacizumab plus chemotherapy as first-line treatment for advanced non-squamous non-small cell lung cancer (nsNSCLC) remains unclear. The study aimed to compare the effectiveness of the two regimens in advanced nsNSCLC. What were the results? We found that PD-1-targeted immune checkpoint inhibitor plus chemotherapy was superior to bevacizumab plus chemotherapy as first-line treatment for advanced nsNSCLC without driver gene mutations, however this conclusion is debatable for patients with PD-L1 〈 1%. What do the results of the study mean? Current clinical studies that directly comparing PD-1 inhibitor plus chemotherapy and bevacizumab plus chemotherapy are lacking. It is still unclear which of these two regimens was superior as first-line treatment for advanced nsNSCLC, especially for patients with PD-L1 〈 1%. This study confirmed that PD-1 inhibitor plus chemotherapy was superior to bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer (nsNSCLC), but not for those patients with PD-L1 〈 1%. Prospective studies are needed to determine which regimen is better for patients with PD-L1 〈 1%.
Type of Medium:
Online Resource
ISSN:
2042-6305
,
2042-6313
DOI:
10.57264/cer-2023-0006
Language:
English
Publisher:
Becaris Publishing Limited
Publication Date:
2023
detail.hit.zdb_id:
2669725-7
Permalink
